Cover Image
市場調查報告書

骨癌:開發中產品分析

Osteosarcoma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213052
出版日期 內容資訊 英文 223 Pages
訂單完成後即時交付
價格
Back to Top
骨癌:開發中產品分析 Osteosarcoma - Pipeline Review, H2 2016
出版日期: 2016年08月17日 內容資訊: 英文 223 Pages
簡介

骨癌是會破壞組織,造成骨骼脆弱的一種癌症,是骨癌中最常見的一種類型,會從形成新骨骼組織的幼若骨細胞開始惡化。症狀有疼痛、骨折、腫起、發紅、關節可動度有限等。危險因子有年齡,性別,家族病史及李-佛美尼症候群(Li-Fraumeni syndrome)等。骨癌的治療以手術、化療、放射線治療等組合治療最為常見。

本報告涵括全球骨癌治療藥的開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及他們開發中的產品評估等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

骨癌概要

治療藥的開發

  • 骨癌開發中產品:概要
  • 骨癌開發中產品:比較分析

骨癌:開發中的治療藥:各企業

骨癌:開發中的治療藥:大學·各研究機關

骨癌:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

骨癌:開發中的產品:各企業

骨癌:開發中的產品:各大學·研究機關

骨癌:治療藥的開發企業

  • Advaxis, Inc.
  • Amgen Inc.
  • AVEO Pharmaceuticals, Inc.
  • Bayer AG
  • Bellicum Pharmaceuticals, Inc.
  • Celldex Therapeutics, Inc.
  • CytRx Corporation
  • Eleison Pharmaceuticals LLC
  • Exelixis, Inc.
  • Isofol Medical AB
  • MediaPharma s.r.l.
  • Merck & Co., Inc.
  • Merrimack Pharmaceuticals, Inc.
  • Netris Pharma S.A.S.
  • Novartis AG
  • Oncolys BioPharma Inc
  • Pfizer Inc.
  • 鹽野義製藥
  • TEIJIN FIBERS製藥
  • United Therapeutics Corporation

骨癌:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

骨癌:暫停中的計劃

骨癌:開發終止的企劃

骨癌:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8358IDB

Summary

Global Markets Direct's, 'Osteosarcoma - Pipeline Review, H2 2016', provides an overview of the Osteosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Osteosarcoma
  • The report reviews pipeline therapeutics for Osteosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Osteosarcoma therapeutics and enlists all their major and minor projects
  • The report assesses Osteosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Osteosarcoma

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Osteosarcoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Osteosarcoma Overview
  • Therapeutics Development
    • Pipeline Products for Osteosarcoma - Overview
    • Pipeline Products for Osteosarcoma - Comparative Analysis
  • Osteosarcoma - Therapeutics under Development by Companies
  • Osteosarcoma - Therapeutics under Investigation by Universities/Institutes
  • Osteosarcoma - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Osteosarcoma - Products under Development by Companies
  • Osteosarcoma - Products under Investigation by Universities/Institutes
  • Osteosarcoma - Companies Involved in Therapeutics Development
    • Advaxis, Inc.
    • Amgen Inc.
    • AVEO Pharmaceuticals, Inc.
    • Bayer AG
    • Bellicum Pharmaceuticals, Inc.
    • Celldex Therapeutics, Inc.
    • CytRx Corporation
    • Eleison Pharmaceuticals LLC
    • Exelixis, Inc.
    • Isofol Medical AB
    • MediaPharma s.r.l.
    • Merck & Co., Inc.
    • Merrimack Pharmaceuticals, Inc.
    • Netris Pharma S.A.S.
    • Novartis AG
    • Oncolys BioPharma Inc
    • Pfizer Inc.
    • Shionogi & Co., Ltd.
    • Teijin Pharma Limited
    • United Therapeutics Corporation
  • Osteosarcoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 3D-QM - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 3D-QMS - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADXS-HER2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aldoxorubicin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-7209 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AU-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AV-203 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • axitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cabozantinib s-malate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • celyvir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CGS-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cisplatin SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dihydroartemisinin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dinutuximab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glembatumumab vedotin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • irinotecan hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ligerin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LLL-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Modufolin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Osteosarcoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MPE-8.3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NP-137 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OBP-702 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotides to Inhibit Thymidylate Synthase and Dihydrofolate Reductase for Osteosarcoma and Colon Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pazopanib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pembrolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • radium Ra 223 dichloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RSF-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-588410 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SEN-461 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Vitamin D3 Receptor for Osteosarcoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CaMKII for Osteosarcoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • T-2GES - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Osteosarcoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Osteosarcoma - Dormant Projects
  • Osteosarcoma - Discontinued Products
  • Osteosarcoma - Product Development Milestones
    • Featured News & Press Releases
      • Apr 28, 2016: FDA Grants Advaxis Fast Track Designation for ADXS-HER2 for Patients with Newly-Diagnosed, Non-Metastatic, Surgically-Resectable Osteosarcoma
      • Apr 20, 2016: Celldex Therapeutics Presents Data Supporting the Clinical Development of Glembatumumab Vedotin at the AACR Annual Meeting 2016
      • Apr 13, 2016: Sarcoma Foundation of America Honors Advaxis for Advancements in Immunotherapy Platform
      • Mar 23, 2016: Advaxis Hosts Research Reception to Review Late-Breaking ADXS-HER2 at AACR Abstract
      • Mar 21, 2016: Survival Results with Advaxis HER2 Targeted Immunotherapy in Canine Osteosarcoma Published in Clinical Cancer Research
      • Mar 16, 2016: Merrimack to Present on ONIVYDE (irinotecan liposome injection) at the 2016 American Association for Cancer Research Annual Meeting
      • Jan 19, 2016: Advaxis Expands Intellectual Property for Lm Technology Platform
      • Dec 01, 2015: Advaxis Receives Orphan Drug Designation in the European Union for ADXS-HER2 for the Treatment of Osteosarcoma
      • Nov 30, 2015: CapGenesis Files Five Orphan Drug Designation Requests with the FDA and EMA for CGS-200 as a Topical Analgesic
      • Jul 21, 2015: Advaxis Expands Intellectual Property for Lm Technology Platform in HER2
      • May 04, 2015: CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers
      • May 01, 2015: Eleison Announces Successful Completion of Stage 1 of its Phase II Trial of ILC (Inhaled Lipid-complexed Cisplatin) for Pediatric Bone Cancer
      • Apr 28, 2015: Advaxis Enhances Lm-LLO Cancer Immunotherapy Intellectual Property With USPTO Patent Addressing ADXS-HER2
      • Nov 04, 2014: Advaxis to Present Data of ADXS-cHER2 at the Society for Immunotherapy of Cancer 29th Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Osteosarcoma, H2 2016
  • Number of Products under Development for Osteosarcoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Osteosarcoma - Pipeline by Advaxis, Inc., H2 2016
  • Osteosarcoma - Pipeline by Amgen Inc., H2 2016
  • Osteosarcoma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016
  • Osteosarcoma - Pipeline by Bayer AG, H2 2016
  • Osteosarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016
  • Osteosarcoma - Pipeline by Celldex Therapeutics, Inc., H2 2016
  • Osteosarcoma - Pipeline by CytRx Corporation, H2 2016
  • Osteosarcoma - Pipeline by Eleison Pharmaceuticals LLC, H2 2016
  • Osteosarcoma - Pipeline by Exelixis, Inc., H2 2016
  • Osteosarcoma - Pipeline by Isofol Medical AB, H2 2016
  • Osteosarcoma - Pipeline by MediaPharma s.r.l., H2 2016
  • Osteosarcoma - Pipeline by Merck & Co., Inc., H2 2016
  • Osteosarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016
  • Osteosarcoma - Pipeline by Netris Pharma S.A.S., H2 2016
  • Osteosarcoma - Pipeline by Novartis AG, H2 2016
  • Osteosarcoma - Pipeline by Oncolys BioPharma Inc, H2 2016
  • Osteosarcoma - Pipeline by Pfizer Inc., H2 2016
  • Osteosarcoma - Pipeline by Shionogi & Co., Ltd., H2 2016
  • Osteosarcoma - Pipeline by Teijin Pharma Limited, H2 2016
  • Osteosarcoma - Pipeline by United Therapeutics Corporation, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Osteosarcoma - Dormant Projects, H2 2016
  • Osteosarcoma - Dormant Projects (Contd..1), H2 2016
  • Osteosarcoma - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Osteosarcoma, H2 2016
  • Number of Products under Development for Osteosarcoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top